HomeCompareGBIM vs NOBL

GBIM vs NOBL: Dividend Comparison 2026

GBIM yields 2000000.00% · NOBL yields 2.14%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 GBIM wins by $4.879226400974806e+39M in total portfolio value
10 years
GBIM
GBIM
● Live price
2000000.00%
Share price
$0.00
Annual div
$2.00
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$4.879226400974806e+39M
Annual income
$4,878,746,539,330,970,000,000,000,000,000,000,000,000,000,000.00
Full GBIM calculator →
NOBL
NOBL
● Live price
2.14%
Share price
$106.01
Annual div
$2.27
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$22.8K
Annual income
$246.19
Full NOBL calculator →

Portfolio growth — GBIM vs NOBL

📍 GBIM pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodGBIMNOBL
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, GBIM + NOBL cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
GBIM pays
NOBL pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

GBIM
Annual income on $10K today (after 15% tax)
$170,000,000.00/yr
After 10yr DRIP, annual income (after tax)
$4,146,934,558,431,324,500,000,000,000,000,000,000,000,000,000.00/yr
NOBL
Annual income on $10K today (after 15% tax)
$182.19/yr
After 10yr DRIP, annual income (after tax)
$209.26/yr
At 15% tax rate, GBIM beats the other by $4,146,934,558,431,324,500,000,000,000,000,000,000,000,000,000.00/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of GBIM + NOBL for your $10,000?

GBIM: 50%NOBL: 50%
100% NOBL50/50100% GBIM
Portfolio after 10yr
$2.439613200487403e+39M
Annual income
$2,439,373,269,665,485,000,000,000,000,000,000,000,000,000,000.00/yr
Blended yield
99.99%
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

GBIM buys
0
NOBL buys
0
No recent congressional trades found for GBIM or NOBL in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricGBIMNOBL
Forward yield2000000.00%2.14%
Annual dividend / share$2.00$2.27
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR0%0%
Portfolio after 10y$4.879226400974806e+39M$22.8K
Annual income after 10y$4,878,746,539,330,970,000,000,000,000,000,000,000,000,000,000.00$246.19
Total dividends collected$4.879195005460081e+39M$2.3K
Payment frequencyquarterlyquarterly
SectorStockETF

Year-by-year: GBIM vs NOBL ($10,000, DRIP)

YearGBIM PortfolioGBIM Income/yrNOBL PortfolioNOBL Income/yrGap
1← crossover$200,010,700$200,000,000.00$10,914$214.34+$200.00MGBIM
2$3,738,731,768,458$3,738,517,757,009.35$11,897$218.63+$3738731.76MGBIM
3$65,315,062,866,930,490$65,311,062,423,938,240.00$12,952$222.72+$65315062866.92MGBIM
4$1,066,400,830,062,625,000,000$1,066,330,942,945,357,500,000.00$14,086$226.62+$1066400830062625.00MGBIM
5$16,272,182,796,453,826,000,000,000$16,271,041,747,565,660,000,000,000.00$15,302$230.33+$16272182796453826560.00MGBIM
6$232,054,240,113,661,900,000,000,000,000$232,036,828,878,069,680,000,000,000,000.00$16,607$233.85+$2.3205424011366188e+23MGBIM
7$3,092,799,066,104,688,500,000,000,000,000,000$3,092,550,768,067,767,400,000,000,000,000,000.00$18,007$237.18+$3.0927990661046884e+27MGBIM
8$38,524,105,697,352,694,000,000,000,000,000,000,000$38,520,796,402,351,967,000,000,000,000,000,000,000.00$19,508$240.35+$3.8524105697352695e+31MGBIM
9$448,468,826,014,798,700,000,000,000,000,000,000,000,000$448,427,605,221,702,600,000,000,000,000,000,000,000,000.00$21,116$243.35+$4.484688260147987e+35MGBIM
10$4,879,226,400,974,806,000,000,000,000,000,000,000,000,000,000$4,878,746,539,330,970,000,000,000,000,000,000,000,000,000,000.00$22,841$246.19+$4.879226400974806e+39MGBIM

GBIM vs NOBL: Complete Analysis 2026

GBIMStock

GlobeImmune, Inc., a biopharmaceutical company, focuses on developing therapeutic products for cancer and infectious diseases based on proprietary Tarmogen platform. Its product candidate includes GS-4774, which is in Phase 2 trials for the treatment of patients with chronically infected with hepatitis B virus, as well as with oral antiviral suppressive therapy. The company is also involved in developing GI-6301 for the treatment of cancers expressing the brachyury protein; and GI-6207 that is in Phase 2 clinical trials to treat medullary thyroid cancer. In addition, it is involved in developing GI-4000, which is in Phase 2b clinical trials for the treatment of resected pancreas cancer; and is in Phase 2 clinical trial to treat non-small cell lung cancer, as well as is in Phase 2 clinical trial for the treatment of colorectal cancer. Further, the company is involved in developing various other product candidates targeting various infectious diseases that are in preclinical development stage, which include GI-19000 to treat tuberculosis; GI-2010 for the treatment of human immunodeficiency virus; and GI-18000 for hepatitis D virus infection. It has strategic collaborations with Gilead Sciences, Inc. and Celgene Corporation. The company was formerly known as Ceres Pharmaceuticals, Inc. and changed its name to GlobeImmune, Inc. in May 2001. GlobeImmune, Inc. was founded in 1995 and is headquartered in Louisville, Colorado.

Full GBIM Calculator →

NOBLETF

The fund will invest at least 80% of its total assets in component securities of the index. The index contains a minimum of 40 stocks, which are equally weighted, and no single sector is allowed to comprise more than 30% of the index weight. It seeks to remain fully invested at all times in securities and/or financial instruments that, in combination, provide exposure to the returns of the index without regard to market conditions, trends or direction.

Full NOBL Calculator →
📬

Get this GBIM vs NOBL comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

GBIM vs SCHDGBIM vs JEPIGBIM vs OGBIM vs KOGBIM vs MAIN

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.